trial · primary record
Trastuzumab Deruxtecan
Ovarian Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 582 |
| Primary completion | 2032-01-31 |
| Primary endpoint | Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) in the HER2 IHC 3+/2+ Population |
| Registry ID | NCT06819007 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:56.909Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06819007
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Trastuzumab Deruxtecan · compound